Compare Boston Scientific Corporation (BSX) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Kinross Gold Corporation — how do they compare? Boston Scientific Corporation trades at $42.76 (market cap $66.37B), while Kinross Gold Corporation trades at $23.88 (market cap $28.24B). The key difference: Boston Scientific Corporation is far larger — about 2.4× Kinross Gold Corporation's market cap, and Kinross Gold Corporation pays a 0.61% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | KGC | |
|---|---|---|
Market Cap | $66.37B | $28.24B |
Sector | Health | Basic Materials |
52-Week High | $108.14 | $38.06 |
52-Week Low | $42.63 | $15.33 |
Enterprise Value | $75.94B | $26.80B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
KGC trades at $23.48, down 2.73% on the day, amid a bearish technical signal. Fundamentally, the company shows robust health with revenue growth from $3.5B in 2022 to $7.05B in 2025 and a net income margin of 35.99%. Recent quarters have consistently beaten EPS estimates. Analyst consensus is bullish with a $37.20 price target, though technical indicators suggest near-term pressure.
The outlook for KGC is positive based on strong fundamentals and growth trajectory, but investors face near-term technical headwinds and sensitivity to gold prices. The stock presents a value opportunity with a low P/E of 9.99, though execution on production guidance and cost management remain key to realizing upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
